Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer

  • Rutger J. Dost
  • Andor W. J. M. Glaudemans
  • Anthonius J. Breeuwsma
  • Igle J. de Jong
Original Article

DOI: 10.1007/s00259-013-2398-7

Cite this article as:
Dost, R.J., Glaudemans, A.W.J.M., Breeuwsma, A.J. et al. Eur J Nucl Med Mol Imaging (2013) 40(Suppl 1): 41. doi:10.1007/s00259-013-2398-7

Abstract

Purpose

Recurrent prostate cancer is usually treated by combining radiotherapy and androgen deprivation therapy. To stage the cancer, choline positron emission tomography (PET)/CT can be performed. It is generally thought that androgen deprivation therapy does not influence choline PET/CT. In this article we focus on the molecular backgrounds of choline and androgens, and the results of preclinical and clinical studies performed using PET/CT.

Methods

Using PubMed, we looked for the relevant articles about androgen deprivation therapy and choline PET/CT.

Results

During ADT, a tendency of decreased uptake of choline in prostate cancer was observed, in particular in hormone-naïve patients.

Conclusion

We conclude that in order to prevent false-negative choline PET/CT scans androgen deprivation should be withheld prior to scanning, especially in hormone-naïve patients.

Keywords

Recurrent prostate cancerCholine PET/CTAndrogen deprivation therapyHormone-naïve prostate cancerCastration-resistant prostate cancer

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Rutger J. Dost
    • 1
  • Andor W. J. M. Glaudemans
    • 2
  • Anthonius J. Breeuwsma
    • 1
  • Igle J. de Jong
    • 1
  1. 1.Department of UrologyUniversity of Groningen, University Medical Center GroningenGroningenThe Netherlands
  2. 2.Nuclear Medicine and Molecular ImagingUniversity of Groningen, University Medical Center GroningenGroningenThe Netherlands